Article: Collegium Pharmaceutical Announces the Sale of AllerNaze™ to Lupin.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced that Lupin has acquired all worldwide rights to AllerNaze™ (triamcinolone acetonide, USP) Nasal Spray, 50 mcg. AllerNaze™ is an aqueous based intranasal steroid (INS) product indicated for the once daily treatment of nasal symptoms associated with both seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and children twelve (12) years of age and older that was approved by the U.S. Food and Drug Administration (FDA) in January 2009.

AllerNaze™ will compete in the approximately $2.5 billion a year United States market for INS products for the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!